Analyzing Ensysce Biosciences (NASDAQ:ENSC) and Rhythm Pharmaceuticals (NASDAQ:RYTM)

Ensysce Biosciences (NASDAQ:ENSC) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares Ensysce Biosciences and Rhythm Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07 million	0.85	-$10.18 million	($4.22)	-0.11
Rhythm Pharmaceuticals	$189.76 million	30.37	-$196.54 million	($3.11)	-27.14

Ensysce Biosciences has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Ensysce Biosciences and Rhythm Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1	0	0	0	1.00
Rhythm Pharmaceuticals	1	2	15	1	2.84

Rhythm Pharmaceuticals has a consensus price target of $131.13, indicating a potential upside of 55.38%. Given Rhythm Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Ensysce Biosciences.

Profitability

This table compares Ensysce Biosciences and Rhythm Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-200.87%	-426.62%	-195.53%
Rhythm Pharmaceuticals	-103.57%	-266.56%	-45.01%

Risk and Volatility

Ensysce Biosciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.

Insider & Institutional Ownership

5.6% of Ensysce Biosciences shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Rhythm Pharmaceuticals beats Ensysce Biosciences on 12 of the 15 factors compared between the two stocks.

About Ensysce Biosciences

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.